US 12,433,933 B2
Methods of diagnosing cervical cancer based on altered polypeptide expression and treatment thereof
Alberto Checa Rojas, Morelos (MX); Orlando Santillan Godinez, Morelos (MX); and Raul Dominguez Palestino, Mexico City (MX)
Assigned to TIMSER, S.A.P.I. DE C.V., Mexico City (MX)
Filed by TIMSER, S.A.P.I. DE C.V., Mexico City (MX)
Filed on Aug. 23, 2023, as Appl. No. 18/454,391.
Application 18/454,391 is a division of application No. 16/879,748, filed on May 20, 2020, granted, now 11,771,740.
Claims priority of application No. MX/A/2019/005940 (MX), filed on May 21, 2019.
Prior Publication US 2024/0091305 A1, Mar. 21, 2024
Int. Cl. A61K 38/16 (2006.01); G01N 33/52 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)
CPC A61K 38/16 (2013.01) [G01N 33/52 (2013.01); G01N 33/53 (2013.01); G01N 33/57411 (2013.01)] 20 Claims
 
1. A method comprising:
a) detecting altered expression of at least one polypeptide in a sample from a subject; wherein the at least one polypeptide comprises:
protein 1 containing fibronectin domain type III, L-lactate dehydrogenase chain B, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, rho 23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type-5, heterogeneous nuclear ribonucleoproteins A2/B1, histone H2B type 1-B, homolog of DnaJ subfamily c member 13, beta enolase and, glutathione S-transferase P; and
b) diagnosing cervical cancer or a cervical lesion based on the detection of the altered expression of said at least one polypeptide; and
c) administering a cervical cancer or cervical lesion treatment to the subject, wherein the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy and immunotherapy.